Ann: BTX 1503 Acne Phase 2 Study Results Presentation, page-529

Okay, I feel much better after reading that. Especially this part which relegates the unfortunate results to history and cleanses the move forward. Given the cost to re-run P2 - which would have likely had a detrimental effect on the stock anyway - they are just getting on with it. Gain back that lost 50% over the next Quarter and move on.

This part clarifies it for me;

"Our AD drug (BTX1204 targeting Atopic Dermatitis) wasn't produced this way (as it was in Phase 2), and Phase 3 (for BTX1503) won't be produced this way. So the event that occurred is now in the past and we don't believe it will occur again. Now that we have the supply agreement with the world's largest CBD supplier, we're going to make everything for the Phase 3 study out of our US facility. And we will control it. We will produce it, test it, test it some more, and then test it again, making sure it's ready for the study," said Vince Ippolito, President & Executive Chairman of Botanix Pharma.

Thanks for posting, that was most helpful.